This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Wenandy, L. Articles by Andersen, M. H. Search for Related Content PubMed PubMed Citation Articles by Wenandy, L. Articles by Andersen, M. H.

The Immunogenicity of the hTERT540-548 Peptide in Cancer

Authors' Affiliations: ¹ Center for Cancer Immune Therapy, Department of Hematology, and ² Department of Oncology, Herlev University Hospital, Herlev, Denmark

Requests for reprints: Mads Hald Andersen, Center for Cancer Immune Therapy, Department of Hematology, Herlev University Hospital, Dk-2730 Herlev, Denmark. Phone: 45-4488-4488; Fax: 45-4453-0176; E-mail: mahaan01{at}heh.regionh.dk.

Human telomerase reverse transcriptase (hTERT), the catalytic subunit of telomerase, is an attractive target antigen for cancer immunotherapy due to its expression in the vast majority of human tumors. The first immunogenic peptide described from hTERT was the HLA-A2–restricted peptide hTERT540 (ILAKFLHWL). However, much discrepancy exists about the processing and presentation of this epitope on the surface of neoplastic cells. Originally, it was described that specific CTL can be generated in vitro and that such cells are able to kill a range of hTERT⁺ tumor cell lines and primary tumors in a peptide-specific, HLA-A2–restricted fashion. Furthermore, it was described that vaccination of cancer patients with hTERT540 introduced functional antitumor CD8⁺ T cells in patients. More recently, it was described that most patients with cancer have circulating hTERT540-specific CD8⁺ T lymphocytes. In contrast, several other studies have concluded that hTERT540 is not presented on the surface of tumor cells and that immunization of cancer patients with hTERT540 leads to the introduction of specific T cells that do not recognize tumor cells in vivo. In the present commentary, we summarize these highly contradictive results about this potentially very important T-cell epitope. Furthermore, we describe novel data showing that naturally occurring immune responses against hTERT540 are, although rare, present in cancer patients and that such hTERT540-specific T cells are able to recognize and kill cancer cells. Hence, our data support the findings that hTERT540 peptide is presented by human tumors and can be a target for CTL-mediated tumor lysis.